Advertisements


Roche"s Rituxan Gets Priority Review for Blood Disorder

Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children .....»»

Category: personnelSource: nytJun 12th, 2019

Genentech says Rituxan granted Priority Review by FDA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 12th, 2019

Benzinga"s Daily Biotech Pulse: Epidiolex, Roche"s Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 25) read more.....»»

Category: blogSource: benzingaJun 26th, 2018

Roche"s (RHHBY) BLA for Lymphoma Drug Gets Priority Review

The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, an.....»»

Category: dealsSource: nytFeb 19th, 2019

Roche"s (RHHBY) BLA for Lymphoma Drug Gets Priority Review

Zacks.....»»

Category: topSource: redinewsFeb 20th, 2019

AstraZeneca Shares Trade Higher After FDA Grants Breast Cancer Drug Priority Review

AstraZeneca plc (NYSE: AZN) and partner DAIICHI SANKYO/S ADR (OTC: DSNKY) announced positive news Thursday on their HER-2 targeting antibody drug conjugate, or ADC. read more.....»»

Category: blogSource: benzingaOct 17th, 2019

AstraZeneca says trastuzumab deruxtecan granted FDA Priority Review

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 17th, 2019

RedHill Biopharma says NDA for RHB-105 under priority review by FDA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 26th, 2019

Will This Ebola Vaccine Be the Next Big Thing?

NewLink Genetics shares jumped on Wednesday after the firm announced that the FDA has accepted Merck’s Biologics License Application and granted priority review for the investigational Ebola vaccine......»»

Category: blogSource: 247wallstSep 18th, 2019

NewLink Genetics Rallies After Ebola Vaccine Granted Priority Review Status

NewLink Genetics Corp (NASDAQ: NLNK) shares are poised to break above the $2 psychological barrier for the first time since early April after the company issued a regulatory update on a partne read more.....»»

Category: blogSource: benzingaSep 18th, 2019

Merck: FDA accepts BLA, grants priority review for investigational Ebola vaccine

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 17th, 2019

Merck"s V920 Ebola treatment granted priority review by the FDA

Merck & Co. Inc. said Tuesday the Food and Drug Administration has acc.....»»

Category: topSource: marketwatchSep 17th, 2019

Peach Bowl Inc. donates $20 million to fund clinical trials

Peach Bowl Inc., which owns the Chick-fil-A Peach Bowl, is all in on tackling childhood cancer. The Peach Bowl, a non-profit organization, announced a $20 million gift to The Aflac Center and Blood Disorder Center of Children’s Healthcare of Atlant.....»»

Category: topSource: bizjournalsSep 17th, 2019

Seattle Genetics, Astella: FDA grants priority review for enfortumab vedotin BLA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 16th, 2019

Seattle Genetics, Astellas Pharma get FDA priority review for enfortumab vedotin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 16th, 2019

$5M grant to help Wash U research blood disorder therapies

The Washington University School of Medicine has received a $5 million grant from the Edward P. Evans Foundation to create a new center that will research rare blood disorders. The center will focus on a specific set of disorders, called myelodysplast.....»»

Category: topSource: bizjournalsSep 12th, 2019

Horizon Pharma granted priority review for teprotumumab by FDA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: worldSource: nytSep 9th, 2019

$4.3B deal delayed again: Roche extends Spark Therapeutics offer for sixth time

The slow-moving regulatory review process is once again being blamed for the latest delay in Roche’s proposed $4.3 billion acquisition of Philadelphia gene therapy pioneer Spark Therapeutics Inc. Roche said on Monday it is extending the offering per.....»»

Category: topSource: bizjournalsSep 3rd, 2019

AstraZeneca agrees to buy FDA Priority Review Voucher from Sobi for $95M

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 22nd, 2019

Pfizer says FDA grants XTANDI application priority review

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 21st, 2019

Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder

Shares of Cerecor Inc. rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S. Food and Drug Administration has awarded it an expedited review process for a treatment for Manno.....»»

Category: topSource: marketwatchAug 21st, 2019